Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: further evidence that CLN3P has anti-apoptotic properties.

Narayan SB, Rakheja D, Pastor JV, Rosenblatt K, Greene SR, Yang J, Wolf BA, Bennett MJ.

Mol Genet Metab. 2006 Jun;88(2):178-83. Epub 2006 Mar 3.

PMID:
16515873
2.

Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update.

Rakheja D, Narayan SB, Bennett MJ.

Curr Mol Med. 2007 Sep;7(6):603-8. Review.

PMID:
17896996
3.

CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.

Rusyn E, Mousallem T, Persaud-Sawin DA, Miller S, Boustany RM.

Pediatr Res. 2008 Jun;63(6):625-31. doi: 10.1203/PDR.0b013e31816fdc17.

PMID:
18317235
4.

CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.

Narayan SB, Pastor JV, Mitchison HM, Bennett MJ.

Brain. 2004 Aug;127(Pt 8):1748-54. Epub 2004 Jul 7.

5.

Screening for calcium channel modulators in CLN3 siRNA knock down SH-SY5Y neuroblastoma cells reveals a significant decrease of intracellular calcium levels by selected L-type calcium channel blockers.

An Haack K, Narayan SB, Li H, Warnock A, Tan L, Bennett MJ.

Biochim Biophys Acta. 2011 Feb;1810(2):186-91. doi: 10.1016/j.bbagen.2010.09.004. Epub 2010 Oct 7.

6.

Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein.

Ezaki J, Takeda-Ezaki M, Koike M, Ohsawa Y, Taka H, Mineki R, Murayama K, Uchiyama Y, Ueno T, Kominami E.

J Neurochem. 2003 Dec;87(5):1296-308.

7.

The Batten disease gene product (CLN3p) is a Golgi integral membrane protein.

Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, Sutherland GR, Callen DF.

Hum Mol Genet. 1999 Mar;8(3):523-31.

8.

Amlodipine prevents apoptotic cell death by correction of elevated intracellular calcium in a primary neuronal model of Batten disease (CLN3 disease).

Warnock A, Tan L, Li C, An Haack K, Narayan SB, Bennett MJ.

Biochem Biophys Res Commun. 2013 Jul 12;436(4):645-9. doi: 10.1016/j.bbrc.2013.04.113. Epub 2013 Jun 13.

PMID:
23769828
9.

Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.

Dhar S, Bitting RL, Rylova SN, Jansen PJ, Lockhart E, Koeberl DD, Amalfitano A, Boustany RM.

Ann Neurol. 2002 Apr;51(4):448-66.

PMID:
11921051
10.

Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease.

Järvelä I, Sainio M, Rantamäki T, Olkkonen VM, Carpén O, Peltonen L, Jalanko A.

Hum Mol Genet. 1998 Jan;7(1):85-90.

11.

Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL)

Järvelä I, Lehtovirta M, Tikkanen R, Kyttälä A, Jalanko A.

Hum Mol Genet. 1999 Jun;8(6):1091-8. Erratum in: Hum Mol Genet 1999 Aug;8(8):1585.

12.

CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease.

Luiro K, Kopra O, Lehtovirta M, Jalanko A.

Hum Mol Genet. 2001 Sep 15;10(19):2123-31.

13.

Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.

Chan CH, Ramirez-Montealegre D, Pearce DA.

Neuropathol Appl Neurobiol. 2009 Apr;35(2):189-207. doi: 10.1111/j.1365-2990.2008.00984.x.

PMID:
19284480
14.

Deletion of the Caenorhabditis elegans homologues of the CLN3 gene, involved in human juvenile neuronal ceroid lipofuscinosis, causes a mild progeric phenotype.

de Voer G, van der Bent P, Rodrigues AJ, van Ommen GJ, Peters DJ, Taschner PE.

J Inherit Metab Dis. 2005;28(6):1065-80.

PMID:
16435200
15.

The CLN3 gene is a novel molecular target for cancer drug discovery.

Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, Jansen PJ, Proia AD, Boustany RM.

Cancer Res. 2002 Feb 1;62(3):801-8.

16.

Osmoregulation of ceroid neuronal lipofuscinosis type 3 in the renal medulla.

Stein CS, Yancey PH, Martins I, Sigmund RD, Stokes JB, Davidson BL.

Am J Physiol Cell Physiol. 2010 Jun;298(6):C1388-400. doi: 10.1152/ajpcell.00272.2009. Epub 2010 Mar 10.

17.

CLN3P, the Batten's disease protein, is a novel palmitoyl-protein Delta-9 desaturase.

Narayan SB, Rakheja D, Tan L, Pastor JV, Bennett MJ.

Ann Neurol. 2006 Nov;60(5):570-7.

PMID:
17036287
18.

Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).

Seigel GM, Lotery A, Kummer A, Bernard DJ, Greene ND, Turmaine M, Derksen T, Nussbaum RL, Davidson B, Wagner J, Mitchison HM.

Mol Cell Neurosci. 2002 Apr;19(4):515-27.

PMID:
11988019
19.

Investigation of Batten disease with the yeast Saccharomyces cerevisiae.

Pearce DA, Sherman F.

Mol Genet Metab. 1999 Apr;66(4):314-9.

PMID:
10191120
20.

Defective lysosomal arginine transport in juvenile Batten disease.

Ramirez-Montealegre D, Pearce DA.

Hum Mol Genet. 2005 Dec 1;14(23):3759-73. Epub 2005 Oct 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk